Fig. 5
From: Construction of a Vero cell line expression human KREMEN1 for the development of CVA6 vaccines
Immunogenicity andin vivo protection of the purified CVA6-TW-00141 particles. (A) The animal experiment was performed following the procedures explained in the schematic diagram. Groups of 6–8 weeks old BALB/c mice were immunized i.p. with the inactivated CVA6 particles prepared on either Vero-KRM1_#11 or RD cells. A control group was inoculated with adjuvant alone. Each mice was immunized at weeks 0 and 2 with a dosage of 1.5 μg (n = 5 per group), and subsequently bled at weeks 0, 4, 6, 8 and 10. The green arrows represent immunization, and the red arrows represent blood collection. (B and C) Antibody response induced by CVA6 particles in mice was measured. Serum anti-CVA6 IgG titer (B) and neutralizing titer (C) were presented as the geometric mean titre (GMT) and converted to the logarithmic scale. The values are expressed as the mean ± SD. Significance was determined using unpaired Student’s t test. n.s., not significant. (D-F)In vivo animal protective efficacy of antisera collected from mice immunized with the CVA6 particles prepared on Vero-KRM1_#1. One-day-old BALB/c mice were firstly administered with diluted antisera 6 h before challenged with CVA6-TW-00141 strain. Mice were monitored daily for survival (D), clinical illness (E) and weight (F) until 20 dpi. Experiments were repeated independently twice, and one representative result is shown. Survival curves were compared by the log-rank (Mantel-Cox) test. (n = 6; ***p < 0.001)